Product Description
Pegadria 20 Mg Injection is a best-seller antineoplastic solution, renowned for its top-drawer efficacy in treating ovarian cancer, multiple myeloma, and AIDS-related Kaposi's sarcoma. With its world-class formulation of Pegylated Liposomal Doxorubicin, Pegadria offers a rare fusion of potency and customizable dosing, as prescribed by medical professionals. This imported, allopathic medicine arrives in a glass vial, ready for intravenous administration. Each red-orange injection is designed for both adults and pediatric patients who require tailored chemotherapy. Stringent manufacturing ensures a 24-month shelf life. Only available via prescription from authorized dealers, suppliers, and exporters across India.
Versatile Application & Exceptional Features
Pegadria 20 Mg Injection demonstrates terrific application flexibility, suitable for both adults and pediatric patients under medical supervision. Its primary uses include targeted treatment for ovarian cancer, multiple myeloma, and AIDS-related Kaposi's sarcoma. The product's rare composition enables reduced side effects thanks to pegylation, while its intravenous delivery ensures rapid action. Its customizable dosing allows precise administration based on patient needs, broadening its general and specific healthcare utility.
Robust Distribution & Trusted Certifications
Pegadria 20 Mg Injection leads the domestic market across India with a strong network of dealers, distributors, and certified suppliers. Secure shipping and reliable transport services ensure delivery with product integrity uncompromised. Each unit features verified certifications and detailed package inserts. Terrific supply ability and competitive sale price make Pegadria accessible to retailers and wholesalers nationwide, backed by timely availability and full regulatory compliance.
FAQ's of Pegadria 20 Mg Injection:
Q: How should Pegadria 20 Mg Injection be administered?
A: Pegadria 20 Mg Injection is administered intravenously by medical professionals, following the dosage prescribed by a physician. It is not for self-administration and must be given in a clinical setting.
Q: What conditions is Pegadria 20 Mg Injection approved to treat?
A: This injection is indicated for treating ovarian cancer, multiple myeloma, and AIDS-related Kaposi's sarcoma, offering potent oncology benefits in these applications.
Q: What are the main side effects of Pegadria 20 Mg Injection?
A: Common side effects include nausea, vomiting, alopecia, mucositis, myelosuppression, and palmar-plantar erythrodysesthesia. Consult your physician for complete information and management strategies.
Q: When should Pegadria 20 Mg Injection not be used?
A: Pegadria should not be used in patients with hypersensitivity to doxorubicin or any component of the injection, severe myelosuppression, or a history of recent myocardial infarction.
Q: Where should Pegadria 20 Mg Injection be stored?
A: Store the vials at 2C to 8C. Do not freeze and protect from light to maintain product efficacy and safety until the expiration date.
Q: What makes Pegadria a top-drawer choice among chemotherapy agents?
A: Pegadria's pegylated liposomal formulation enables improved drug delivery, reduced toxicities, and customizable dosing options, ensuring superior patient outcomes compared to standard chemotherapy injections.